Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Shareprice 35% below pp price

<< Previous

Bullboard Posts

Next >>

Comment by tylerreddickon Mar 27, 2024 10:21pm

79 Views

Post# 35957103

RE:RE:RE:Shareprice 35% below pp price

MirrorWorldMan wrote: I genuinely think that Howie only needs to produce numbers or even dates for the AbbVie deal. At least provide guidance to when when this dumb company is forecasted to be profitable. Silence perpetuates negative speculation and zero valuations.

Howie handed total control over the AbbVie in that "wonderful" deal he negotiated, and AbbVie doesn't give a rat's behind whether SBM survives or not. They probably would prefer that we didn't, then they could just steal 1067 from us.

So don't expect anything about that for a while yet.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario